{"id":"https://openalex.org/W2581287805","doi":null,"title":"Palbociclib (Ibrance\u00ae) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer","display_name":"Palbociclib (Ibrance\u00ae) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer","alternate_titles":[],"publication_year":2017,"publication_date":"2017-01-01","ids":{"openalex":"https://openalex.org/W2581287805","mag":"2581287805"},"language":"en","primary_location":{"id":"mag:2581287805","doi":null,"is_oa":false,"landing_page_url":"http://eprints.aihta.at/1114/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W2581287805"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5006121692","display_name":"Lynda McGahan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Lynda McGahan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5006121692"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.1212,"has_fulltext":false,"cited_by_count":1,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.46300374,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":93},"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/palbociclib","display_name":"palbociclib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/fulvestrant","display_name":"fulvestrant","score":0.9950000047683716},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.8809999823570251},{"id":"https://openalex.org/keywords/hormone-receptor-positive-breast-cancer","display_name":"hormone receptor-positive breast cancer","score":0.9319999814033508},{"id":"https://openalex.org/keywords/her2-negative-breast-cancer","display_name":"HER2-negative breast cancer","score":0.9929999709129333},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9380000233650208},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9039999842643738},{"id":"https://openalex.org/keywords/endocrine-resistance","display_name":"endocrine therapy resistance","score":0.6710000038146973},{"id":"https://openalex.org/keywords/rb-phosphorylation","display_name":"retinoblastoma protein phosphorylation","score":0.7490000128746033},{"id":"https://openalex.org/keywords/cell-cycle-regulation","display_name":"cell cycle regulation","score":0.6100000143051147},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.6819999814033508},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7990000247955322},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.33500000834465027},{"id":"https://openalex.org/keywords/drug-efficacy","display_name":"drug efficacy","score":0.34299999475479126},{"id":"https://openalex.org/keywords/aromatase-inhibitors","display_name":"aromatase inhibitors","score":0.6209999918937683}],"concepts":[{"id":"https://openalex.org/C2780482068","wikidata":"https://www.wikidata.org/wiki/Q5508491","display_name":"Fulvestrant","level":5,"score":0.9724115133285522},{"id":"https://openalex.org/C2779744173","wikidata":"https://www.wikidata.org/wiki/Q15269707","display_name":"Palbociclib","level":5,"score":0.9610533714294434},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7022152543067932},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.6653517484664917},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5827127695083618},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5618867874145508},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4601162075996399},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.45946004986763},{"id":"https://openalex.org/C2778812593","wikidata":"https://www.wikidata.org/wiki/Q194974","display_name":"Letrozole","level":5,"score":0.43822330236434937},{"id":"https://openalex.org/C2778504769","wikidata":"https://www.wikidata.org/wiki/Q3040305","display_name":"Aromatase inhibitor","level":5,"score":0.4349956512451172},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.42260122299194336},{"id":"https://openalex.org/C84606932","wikidata":"https://www.wikidata.org/wiki/Q416496","display_name":"Estrogen receptor","level":4,"score":0.27722087502479553},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.18245083093643188},{"id":"https://openalex.org/C2777176818","wikidata":"https://www.wikidata.org/wiki/Q412178","display_name":"Tamoxifen","level":4,"score":0.12702101469039917}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2581287805","doi":null,"is_oa":false,"landing_page_url":"http://eprints.aihta.at/1114/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2903708181","https://openalex.org/W2470394874","https://openalex.org/W4254399222","https://openalex.org/W2182070232","https://openalex.org/W1894737434","https://openalex.org/W3010200524","https://openalex.org/W2886243066","https://openalex.org/W2657500078","https://openalex.org/W1949713501","https://openalex.org/W2061818721"],"abstract_inverted_index":{"As":[0],"key":[1],"cell":[2,24,31,60],"cycle":[3,32,61],"regulators,":[4],"cyclin-dependent":[5],"kinases":[6],"4":[7,287],"and":[8,184,275,289,295,302,304,365,381,403],"6":[9],"(CDK4/6)":[10],"interact":[11],"with":[12,101,107,128,223,240,323,334],"cyclin":[13,42],"D,":[14],"to":[15,147,195,199,215,237,369,375],"hyperphosphorylate":[16],"retinoblastoma":[17],"(Rb),":[18],"releasing":[19],"transcription":[20],"factors":[21],"that":[22],"allow":[23],"proliferation.":[25],"During":[26],"cancer,":[27],"dysregulation":[28],"of":[29,36,41,53,80,177,226,249,256,269,278,297,306,378,384,407],"the":[30,72,78,121,132,213,376,390,394],"occurs":[33],"through":[34],"loss":[35],"Rb":[37,56,391],"function,":[38],"or":[39,44,94,106,114,152,286,332,338,358],"amplification":[40],"D":[43],"CDK.":[45],"Palbociclib":[46,123,186,313],"(Ibrance\u2122),":[47],"a":[48,315],"reversible,":[49],"small":[50],"molecule":[51],"inhibitor":[52,104,318],"CDK4/6":[54,317],"blocks":[55],"phosphorylation,":[57],"thus":[58],"preventing":[59],"progression.":[62],"In":[64,120],"November":[65],"2016,":[66],"palbociclib":[67,148,241,257,271,298,342,399],"received":[68],"marketing":[69],"authorisation":[70],"by":[71,346,355],"European":[73],"Medicines":[74],"Agency":[75],"(EMA)":[76],"for":[77,230,319,328,398,409],"treatment":[79,327],"hormone":[81],"receptor":[82,89],"(HR)":[83],"positive,":[84],"human":[85],"epidermal":[86],"growth":[87],"factor":[88],"(HER2)":[90],"negative":[91],"locally":[92],"advanced":[93,331],"metastatic":[95],"breast":[96],"cancer":[97],"(MBC)":[98],"in":[99,109,126,138,212,254,266,293,321,362,372],"combination":[100,127,322],"an":[102],"aromatase":[103],"(AI),":[105],"fulvestrant":[108,129,150,155,188,202,243,245,273,282,300,309,324],"women":[110,143],"who":[111],"progress":[112],"during":[113,337],"following":[115,339],"endocrine":[116],"therapy":[117,373],"(ET).":[118],"US,":[122],"is":[124,314,351,393],"authorised":[125],"based":[130],"on":[131],"multicentre,":[133],"phase":[134],"III":[135],"PALOMA-3":[136],"trial,":[137],"which":[139],"521":[140],"HR-positive,":[141,329],"HER2-negative":[142,330],"were":[144,220,253,291],"randomised":[145],"2:1":[146],"plus":[149,154,187,201,242,272,281,299,308],"(n=347)":[151],"placebo":[153,200,280,307],"(n=174).":[156],"The":[157],"primary":[158],"endpoint":[159,350],"was":[160],"investigator-assessed":[161],"progression-free":[162],"survival":[163,169],"(PFS);":[164],"secondary":[165],"endpoints":[166],"included":[167],"overall":[168],"(OS),":[170],"confirmed":[171],"objective":[172],"response":[173,178],"rate":[174],"(ORR),":[175],"duration":[176],"(DOR),":[179],"patient":[180,366],"reported":[181,292],"outcomes":[182],"(PROs)":[183],"safety.":[185],"increased":[189,233,343],"median":[190,344],"PFS":[191,345],"from":[192,234],"4.6":[193],"months":[194,197,236,239],"9.5":[196],"compared":[198],"(HR":[203],"0.46,":[204],"95%":[205],"CI":[206],"0.36-0.59;":[207],"two-sided,":[208],"p":[209],"<":[210],"0.0001)":[211],"intention":[214],"treat":[216],"population.":[217],"OS":[218,356,379],"data":[219,357,380],"not":[221,352],"mature":[222],"only":[224,395],"29%":[225],"197":[227],"events":[228,263],"needed":[229],"analysis.":[231],"DOR":[232],"7.6":[235],"9.3":[238],"versus":[244,259,386],"alone.":[246],"Global":[247],"quality":[248],"life":[250],"(QoL)":[251],"results":[252],"favour":[255],"(66.1":[258],"63.0).":[260],"Serious":[261],"adverse":[262],"(SAEs)":[264],"occurred":[265],"44":[267],"(13%)":[268],"345":[270],"recipients":[274,310],"30":[276],"(17%)":[277],"172":[279],"recipients.":[283],"Grade":[284],"3":[285],"neutropenia":[288],"leukopenia":[290],"65%":[294],"28%":[296],"recipients,":[301],"1%":[303],"4%":[305],"respectively.":[311],"first-in-class":[316],"use":[320],"as":[325],"second-line":[326],"MBC":[333],"disease":[335],"progression":[336],"ET.":[340],"While":[341,389],"4.9":[347],"months,":[348],"this":[349],"currently":[353],"supported":[354],"clinically":[359],"important":[360],"differences":[361],"QoL.":[363],"Physician":[364],"preference":[367],"contribute":[368],"palbociclib's":[370],"place":[371],"due":[374],"lack":[377],"head-to-head":[382],"comparisons":[383],"first-line":[385],"subsequent-line":[387],"use.":[388,411],"protein":[392],"reliable":[396],"indicator":[397],"activity,":[400],"further":[401],"indicators":[402],"biomarkers":[404],"may":[405],"be":[406],"benefit":[408],"future":[410]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2581287805","counts_by_year":[{"year":2017,"cited_by_count":1}],"updated_date":"2025-11-06T04:12:42.849631","created_date":"2017-02-03T00:00:00"}
